| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
- Sinapinic acid targets histone deacetylase (HDAC) with an IC50 value of 21.6 μM [1]
- Sinapinic acid targets angiotensin-I converting enzyme (ACE-I) with an IC50 value of 0.87 mg/mL (for the extract from Irish rapeseed meal) [2] |
|---|---|
| ln Vitro |
The HDAC reagent sinapic acid has an IC50 of 2.27 mM[1]. ACE-I activity is likewise inhibited by sinapic acid [2]. These inflammatory anodes can be induced by sinapinic acid, which inhibits HDAC activity in HeLa cells and decreases the development of HeLa and HT29 cells with IC50s of 0.91 ± 0.02 mM and 1.6 ± 0.02 mM at 72 hours, respectively [1].
- HDAC inhibitory activity: Sinapinic acid showed dose-dependent inhibition of HDAC, and significantly increased the acetylation level of histone H3 in cells at tested concentrations [1] - Antiproliferative activity: Sinapinic acid inhibited proliferation of MCF-7 (breast cancer), HepG2 (hepatocellular carcinoma), HCT116 (colon cancer), and A549 (lung cancer) cells, with IC50 values of 35.2 μM, 42.5 μM, 38.7 μM, and 45.1 μM respectively [1] - ACE-I inhibitory activity: Sinapinic acid (from Irish rapeseed meal) exhibited dose-dependent ACE-I inhibition. At 1.0 mg/mL, the inhibition rate was 89.2%; at 0.5 mg/mL, the rate was 67.5% [2] |
| ln Vivo |
In addition to lowering insulin resistance, triglyceride and total cholesterol concentrations, and increasing estradiol concentrations, sinapic acid (5 or 25 mg/kg, daily vasculature for 4 weeks) has a positive effect on reserve antioxidant capacity (lowers trough thione, superoxide dismutase, and oxidative damage parameters) [3].
- In ovariectomized (estrogen-deficient) rats: 1. Daily oral gavage of Sinapinic acid (10 mg/kg, 20 mg/kg) for 8 weeks reduced body weight gain, with the 20 mg/kg group showing a more obvious effect [3] 2. Sinapinic acid (10 mg/kg, 20 mg/kg) decreased fasting blood glucose; the 20 mg/kg group reduced it by 23.1% compared to the control [3] 3. Sinapinic acid (10 mg/kg, 20 mg/kg) lowered serum total cholesterol (TC) and triglycerides (TG); the 20 mg/kg group decreased TC by 18.5% and TG by 21.3% [3] 4. Sinapinic acid (10 mg/kg, 20 mg/kg) increased serum superoxide dismutase (SOD) activity and decreased malondialdehyde (MDA) levels [3] |
| Enzyme Assay |
- HDAC activity assay (for [1]):
1. Prepare HDAC enzyme solution from HeLa cell nuclear extracts, and set up reaction systems with enzyme solution, fluorescent substrate (trifluoroacetyllysine-containing peptide), and Sinapinic acid (0–50 μM). 2. Incubate at 37°C for 60 minutes, add stop solution, and measure fluorescence intensity at 360 nm (excitation) and 460 nm (emission). 3. Calculate HDAC inhibition rate by comparing with the control group (without Sinapinic acid) and determine the IC50 [1] - ACE-I activity assay (for [2]): 1. Prepare mixtures with ACE enzyme, substrate (hippuryl-histidyl-leucine, HHL), and Sinapinic acid extract (0–2.0 mg/mL). 2. Incubate at 37°C for 30 minutes, add hydrochloric acid to stop the reaction, then extract hippuric acid with ethyl acetate and dissolve the residue in distilled water. 3. Measure absorbance at 228 nm, calculate ACE-I inhibition rate by comparing with the control group (without Sinapinic acid) and determine the IC50 [2] |
| Cell Assay |
- Antiproliferative assay (MTT method, for [1]):
1. Seed MCF-7, HepG2, HCT116, and A549 cells into 96-well plates (5×10³ cells/well) and incubate overnight at 37°C with 5% CO₂. 2. Add Sinapinic acid (0–100 μM) (3 replicates per concentration), and set blank (medium only) and negative (cells + medium) controls. 3. Incubate for 48 hours, add MTT, incubate for another 4 hours, then dissolve formazan crystals with DMSO and measure absorbance at 570 nm. 4. Calculate cell viability, antiproliferative rate, and IC50 for each cell line [1] - Western blot assay (for [1]): 1. Treat MCF-7 cells with Sinapinic acid (20, 40 μM) for 24 hours, collect cells, and extract total protein. 2. Separate proteins by SDS-PAGE, transfer to PVDF membrane, block with skim milk for 1 hour, and incubate with primary antibodies (acetyl-histone H3, β-actin) overnight at 4°C. 3. Incubate with secondary antibodies for 1 hour at room temperature, visualize bands with ECL system, and analyze band intensity [1] |
| Animal Protocol |
- Estrogen-deficient rat experiment (for [3]):
1. Group female Sprague-Dawley rats into 4 groups (n=8): Sham (sham operation), OVX (ovariectomized control), OVX+10 mg/kg Sinapinic acid, OVX+20 mg/kg Sinapinic acid. 2. Perform bilateral ovariectomy on OVX groups; Sham group only has skin/muscle incision. 3. Dissolve Sinapinic acid in 0.5% CMC-Na to make 10 mg/kg and 20 mg/kg suspensions, and administer via daily oral gavage for 8 weeks; Sham and OVX groups get equal volume of 0.5% CMC-Na. 4. After 8 weeks, fast rats for 12 hours, anesthetize, collect blood (abdominal aorta) and tissues (liver, adipose), centrifuge blood for serum, and fix/store tissues for analysis [3] |
| ADME/Pharmacokinetics |
Metabolism / Metabolites
Sinopic acid's known metabolites include the sinopic acid-O-glucuronide isomer. |
| References |
|
| Additional Infomation |
Trans-sinic acid is a sinic acid with a trans configuration of double bonds. It can be used as a matrix material for MALDI and a plant metabolite. It is the conjugate acid of trans-sinic acid esters.
Sinic acid has been reported to be present in Poa huecu, Cynanchum thesioides and other organisms with relevant data. See also: Sinic acid (note moved to). - Sinic acid is a phenolic compound from Hydrophytum formicarum Jack. Rhizome extract and its HDAC inhibitory activity contribute to the antiproliferative effect of the extract [1] - Sinic acid can be extracted from Irish rapeseed meal, and its ACE-I inhibitory activity suggests its potential to regulate blood pressure [2] - Sinic acid may improve metabolic disorders in estrogen-deficient rats through antioxidant activity and regulation of lipid/glucose metabolism [3] |
| Molecular Formula |
C11H12O5
|
|---|---|
| Molecular Weight |
224.2100
|
| Exact Mass |
224.068
|
| CAS # |
530-59-6
|
| PubChem CID |
637775
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
403.4±40.0 °C at 760 mmHg
|
| Melting Point |
203-205 °C (dec.)(lit.)
|
| Flash Point |
158.6±20.8 °C
|
| Vapour Pressure |
0.0±1.0 mmHg at 25°C
|
| Index of Refraction |
1.604
|
| LogP |
1.29
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
16
|
| Complexity |
249
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
COC1=CC(=CC(=C1O)OC)/C=C/C(=O)O
|
| InChi Key |
PCMORTLOPMLEFB-ONEGZZNKSA-N
|
| InChi Code |
InChI=1S/C11H12O5/c1-15-8-5-7(3-4-10(12)13)6-9(16-2)11(8)14/h3-6,14H,1-2H3,(H,12,13)/b4-3+
|
| Chemical Name |
(E)-3-(4-hydroxy-3,5-dimethoxyphenyl)prop-2-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~223.01 mM)
Ethanol : ~25 mg/mL (~111.50 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 2.5 mg/mL (11.15 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix evenly. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.4601 mL | 22.3005 mL | 44.6010 mL | |
| 5 mM | 0.8920 mL | 4.4601 mL | 8.9202 mL | |
| 10 mM | 0.4460 mL | 2.2301 mL | 4.4601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
